1.89 USD
↘ 0.04 (1.82%)AT CLOSE (11:59 AM EDT)
ALX Oncology Holdings Inc. Common Stock
ALXONASDAQ • USD
2.03
↗ 0.14 (7.14%)
POST MARKET (AS OF 05:35 PM EDT)
Post Market
AS OF 05:35 PM EDT
2.03
↗ 0.14 (7.14%)
Market: OPEN
ALX Oncology Holdings Inc. Common Stock (ALXO) trades at $2.03 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest ALXO is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 15, 2026.
Open?$1.92
High?$1.92
Low?$1.86
Prev. Close?$1.93
Volume?759.0K
Avg. Volume?987.1K
VWAP?$1.88
Rel. Volume?0.77x
Bid / Ask
Bid?$1.59 × 100
Ask?$2.51 × 100
Spread?$0.92
Midpoint?$2.05
Valuation & Ratios
Market Cap?266.9M
Shares Out?138.3M
Float?102.3M
Float %?76.0%
P/E Ratio?N/A
P/B Ratio?1.96
EPS?-$0.58
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Employees
48
Market Cap
266.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-07-17
Address
323 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-466-7125
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?65
Short Sent.?61
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.84Distress
Confidence?54%Low
Short InterestVery High
Short % of Float?6.91%Elevated
Short Interest?7.1M
Days to Cover?12.3
Free Float102.3M
Avg Daily Volume575.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?9.71Strong
Quick Ratio?9.71Strong
Cash Ratio?1.54Strong
Debt/Equity?0.07Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.96CHEAP▾
Peers100
S&P75
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.1CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-59.4%WEAK▾
S&P3
ROA?-50.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-70950000
Enterprise Value?$253.9M
Fundamentals ratios updated end of day